文献类型：期刊文献

英文题名：Tricuspid valve repair concomitant with mitral valve surgery: a systematic review and meta-analysis

作者：Yi, Kang[1,2];Wang, Wei[3];Xu, Jianguo[2,4];Zhang, Xin[2,5];Wang, Wenxin[2,5];Liu, Chengfei[6];Li, Xinyao[6];You, Tao[1,2,7]

第一作者：Yi, Kang

通信作者：You, T[1]

机构：[1]Gansu Prov Hosp, Dept Cardiovasc Surg, Lanzhou, Gansu, Peoples R China;[2]Gansu Int Sci & Technol Cooperat Base Diag & Treat, Lanzhou, Gansu, Peoples R China;[3]China Med Univ, Hosp 1, Dept Cardiac Surg, Shenyang, Liaoning, Peoples R China;[4]Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China;[5]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Peoples R China;[6]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China;[7]Gansu Prov Hosp, Dept Cardiovasc Surg, 204, Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China

第一机构：Gansu Prov Hosp, Dept Cardiovasc Surg, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Cardiovasc Surg, 204, Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.

年份：2023

卷号：109

期号：7

起止页码：2082

外文期刊名：INTERNATIONAL JOURNAL OF SURGERY

收录：;Scopus(收录号：2-s2.0-85165546236);WOS:【SCI-EXPANDED(收录号:WOS:001035761700025)】；

基金：Natural Science Foundation of Gansu Province (22JR5RA655, 21JR1RA027)

语种：英文

外文关键词：meta-analysis; mitral valve surgery; tricuspid regurgitation; tricuspid valve repair

摘要：Background:Uncertainties persist about whether to aggressively and effectively treat tricuspid regurgitation (TR) during mitral valve (MV) surgery. Review methods:Systematic literature searches were performed in five databases to collect all relevant studies published before May 2022 on whether the tricuspid valve was treated during MV surgery. Separate meta-analyses were performed on data from unmatched studies and randomized controlled trials (RCT)/adjusted studies. Main results:A total of 44 publications were included, of which eight were RCT studies and the rest were retrospective studies. There was no difference in 30-day mortality [odds ratio (OR): 1.00, 95% CI: 0.71-1.42, OR: 0.66, 95% CI: 0.30-1.41)] or overall survival [hazard ratio (HR): 1.01, 95% CI: 0.85-1.19, HR: 0.77, 95% CI: 0.52-1.14] in unmatched studies and RCT/adjusted studies. Late mortality (OR: 0.37, 95% CI: 0.21-0.64) and cardiac-related mortality (OR: 0.36, 95% CI: 0.21-0.62) were lower in the tricuspid valve repair (TVR) group in the RCT/adjusted studies. In the unmatched studies, overall cardiac mortality (OR: 0.48, 95% CI: 0.26-0.88) was lower in the TVR group. In the late TR progression analysis, the late TR progression was lower among patients in the concomitantly intervened tricuspid group, and patients in the untreated tricuspid group were prone to TR progression in both studies (HR: 0.30, 95% CI: 0.22-0.41, HR: 0.37, 95% CI: 0.23-0.58). Conclusions:TVR concomitant with MV surgery is most effective in patients with significant TR and dilated tricuspid annulus, especially those with a significantly reduced risk of distant TR progression.